SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19

We are beyond proud to see our portfolio company SpyBiotech take their COVID-19 vaccine to human trials alongside the Serum Institute of India. What a great day for their team, for science, and for the world at large.

SpyBiotech’s unique protein superglue technology could become a powerful new tool in the fight against infectious diseases and cancer. The success of this trial would provide a meaningful indication of that. As their CEO, Sumi Biswas, says, “our technology can be combined with multiple vaccine delivery platforms to create a plug and display vaccine which is critical for generating vaccines rapidly and safely.”

Read SpyBiotech’s full press release here.

Back to News